StockMarketWire.com - Tiziana Life Sciences, which is developing drugs targeting cancer and inflammatory diseases, said it had received a positive evaluation of tolerability data for a treatment for hepatocellular carcinoma.

An independent data monitor committee recommended an expansion of an initial 11-patient cohort to an additional 20 patients to complete a trial.

'Demonstration of good tolerability with acceptable incidence of serious adverse events is an important milestone,' the company said.


At 9:31am: [LON:TILS] Tiziana Life Sciences Plc share price was +0.75p at 81.75p



Story provided by StockMarketWire.com